PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsCytarabine
Cytarabine, Depocyte(cytarabine)
Cytarabine, DepoCyte, Vyxeos (cytarabine) is a small molecule pharmaceutical. Cytarabine was first approved as Cytarabine on 1982-01-01. It is used to treat leukemia, lymphoma, and meningeal neoplasms in the USA. It has been approved in Europe to treat meningeal neoplasms and myeloid leukemia acute.
Download report
Favorite
Drugs Approved for Childhood Cancers
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
nervous system diseasesD009422
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Combinations
Vyxeos
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cytarabine
Tradename
Company
Number
Date
Products
DEPOCYTPacira BioSciencesN-021041 DISCN1999-04-01
1 products, RLD
CYTARABINETevaN-016793 DISCN1982-01-01
4 products, RLD
Hide discontinued
Cytarabine
+
Daunorubicin
Tradename
Company
Number
Date
Products
VYXEOSCelator PharmaceuticalsN-209401 RX2017-08-03
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
byun rakunapproved drug other2019-03-21
cytarabineANDA2024-07-18
vyxeosNew Drug Application2022-09-27
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
leukemia—D007938C95
lymphoma—D008223C85.9
meningeal neoplasmsEFO_0003851D008577C70
myeloid leukemia acute—D015470C92.0
precursor cell lymphoblastic leukemia-lymphoma—D054198—
Agency Specific
FDA
EMA
Expiration
Code
CYTARABINE / DAUNORUBICIN, VYXEOS, CELATOR PHARMS
2028-03-30ODE-350
2024-08-03ODE-287
2024-03-30NPP
Patent Expiration
Patent
Expires
Flag
FDA Information
Cytarabine / Daunorubicin, Vyxeos, Celator Pharms
100289122032-10-15DPU-3149, U-3150
101661842032-10-15DPU-3149
108354922032-10-15U-3150
80928282029-04-01U-3147
80222792027-09-14DPU-3147
78509902027-01-23DPU-3147
92719312027-01-23DP
85184372026-06-07DP
84318062025-04-22DPU-3147
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01B: Antimetabolites
— L01BC: Pyrimidine analogues, antineoplastic antimetabolites
— L01BC01: Cytarabine
— L01X: Other antineoplastic agents in atc
— L01XY: Combinations of antineoplastic agents
— L01XY01: Cytarabine and daunorubicin
HCPCS
Code
Description
J9098
Injection, cytarabine liposome, 10 mg
J9100
Injection, cytarabine, 100 mg
J9153
Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine
Clinical
Clinical Trials
1630 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C9535654821937741057
Myeloid leukemia acuteD015470—C92.02863741341452730
Myeloid leukemiaD007951—C922573531251246676
LymphomaD008223—C85.981267741329417
Precursor cell lymphoblastic leukemia-lymphomaD054198——77164712223317
Lymphoid leukemiaD007945—C9155138571916255
Myelodysplastic syndromesD009190—D469012925212209
PreleukemiaD011289——691012318163
Non-hodgkin lymphomaD008228—C85.944892948150
SyndromeD013577——56761818130
Show 32 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
RecurrenceD012008——47534—482
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—19387—157
Myelomonocytic leukemia acuteD015479—C92.522195—244
Hematologic neoplasmsD019337——27201—442
Myeloproliferative disordersD009196—D47.115216—541
Monocytic leukemia acuteD007948——16166—237
Erythroblastic leukemia acuteD004915EFO_1001257C94.016135—234
Megakaryoblastic leukemia acuteD007947—C94.215125—232
Acute diseaseD000208——20104—130
Multiple myelomaD009101—C90.06174—328
Show 46 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C802630——553
Blast crisisD001752——714———20
Biphenotypic leukemia acuteD015456—C95.0911——117
PlasmacytomaD010954—C90.326——19
Myeloid leukemia accelerated phaseD015465——44———8
Primary myelofibrosisD055728—D47.433——16
Aids-related lymphomaD016483EFO_1001365——4——15
Nervous system neoplasmsD009423——22——15
B-cell lymphoma marginal zoneD018442—C88.423——14
Pathologic complete responseD000095384——14———4
Show 86 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
T-cell lymphoma cutaneousD016410——1———12
HypersensitivityD006967HP_0012393T78.401————1
Leukemia myeloid chronic atypical bcr-abl negativeD054438—C92.21————1
Neutrophilic leukemia chronicD015467—D47.11————1
Colorectal neoplasmsD015179——1————1
Rectal neoplasmsD012004——1————1
Neoplasms by histologic typeD009370——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ThalassemiaD013789EFO_1001996D56————22
Sickle cell anemiaD000755EFO_0000697D57————11
Hemoglobin sc diseaseD006450EFO_1001797D57.2————11
Hemoglobin c diseaseD006445—D58.2————11
Paroxysmal hemoglobinuriaD006457Orphanet_447D59.12————11
HemoglobinuriaD006456—R82.3————11
MycosesD009181—B35-B49————11
Extranodal nk-t-cell lymphomaD054391—C86.0————11
Sezary syndromeD012751—C84.1————11
Mycosis fungoidesD009182—C84.0————11
Show 40 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCytarabine
INNcytarabine
Description
Cytarabine is a pyrimidine nucleoside in which cytosine is attached to D-arabinofuranose via a beta-N(1)-glycosidic bond. Used mainly in the treatment of leukaemia, especially acute non-lymphoblastic leukaemia, cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. It also has antiviral and immunosuppressant properties. It has a role as an antineoplastic agent, an antimetabolite, an antiviral agent and an immunosuppressive agent. It is a beta-D-arabinoside, a pyrimidine nucleoside and a monosaccharide derivative. It is functionally related to a cytosine.
Classification
Small molecule
Drug classantineoplastics (arabinofuranosyl derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Identifiers
PDB—
CAS-ID147-94-4
RxCUI—
ChEMBL IDCHEMBL803
ChEBI ID28680
PubChem CID6253
DrugBankDB00987
UNII ID04079A1RDZ (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Vyxeos – Jazz Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Depocyte – Pacira BioSciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Cytarabine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 41,526 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cytarabine, Vyxeos
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
53,018 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use